Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

Credit: Shutterstock

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic or a diagnostic for norovirus infections.

The available technology relates to chimpanzee-human chimeric monoclonal antibodies that specifically bind to norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against norovirus and may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or to be used to develop a diagnostic for detection of norovirus infections.

Read more about this exciting collaboration opportunity: or contact Peter Soukas, J.D., 301-496-2644;

Testing Sewage Can Give Schools and Businesses a Heads-Up on the Spread of COVID-19

Karolinska Institute Study Explains Important Cause of Fatal Influenza